首页> 外文期刊>Therapeutics and Clinical Risk Management >Update on Diagnosis and Treatment of Adult Pulmonary Alveolar Proteinosis
【24h】

Update on Diagnosis and Treatment of Adult Pulmonary Alveolar Proteinosis

机译:诊断和治疗成人肺肺泡蛋白病的更新

获取原文
           

摘要

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary surfactant homeostasis disorder resulting in buildup of lipo-proteinaceous material within the alveoli. PAP is classified as primary (autoimmune and hereditary), secondary, congenital and unclassifiable type based on the underlying pathogenesis. PAP has an insidious onset and can, in some cases, progress to severe respiratory failure. Diagnosis is often secured with bronchoalveolar lavage in the setting of classic imaging findings. Recent insights into genetic alterations and autoimmune mechanisms have provided newer diagnostics and treatment options. In this review, we discuss the etiopathogenesis, diagnosis and treatment options available and emerging for PAP.? 2021 Iftikhar et al.
机译:肺部肺泡蛋白酶症(PAP)是一种罕见的肺表面活性剂稳态紊乱,导致肺泡内的脂蛋白质材料的累积。 PAP根据潜在的发病机制归类为归类为主要(自身免疫和遗传性),中等,先天性和无分配的类型。 PAP有一个阴险的发病,在某些情况下可以进展到严重的呼吸衰竭。 在经典成像结果的设置中,诊断通常用支气管肺泡灌洗。 最近对遗传改变和自身免疫机制的见解提供了新的诊断和治疗方案。 在本次审查中,我们讨论了可用的病因athogenesis,诊断和治疗方案,并为PAP进行了新兴。 2021 Iftikhar等。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号